Invitrogen™ ADARB1 Polyclonal Antibody

Catalog No.	Quantity
PIPA5113687	100 μL

Catalog No. PIPA5113687 Supplier Invitrogen™ Supplier No. PA5113687

Description

Rabbit Polyclonal Antibody

Immunogen sequence: NMSSSSTDVK ENRNLDNVSP KDGSTPGPGE GSQLSNGGGG GPGRKRPLEE For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles. Predicted homology: Cow: 83%; Dog: 92%; Horse: 92%; Human: 100%; Mouse: 92%; Rat: 92%.

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.

Specifications

• Antigen: ADARB1
• Applications: Western Blot
• Classification: Polyclonal
• Concentration: 0.5 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with 2% sucrose and 0.09% sodium azide
• Gene: ADARB1
• Gene Accession No.: P78563
• Gene Alias: 1700057H01Rik; Adar2; Adarb1; adenosine deaminase, RNA specific B1; adenosine deaminase, RNA-specific, B1; adenosine deaminase, RNA-specific, B1 (homolog of rat RED1); adenosine deaminase, RNA-specific, B1 (RED1 homolog rat); AW124433; AW558573; BB220382; D10Bwg0447e; Double-stranded RNA-specific editase 1; DRABA2; DRADA2; dsRNA adenosine deaminase; dsRNA adenosine deaminase DRADA2; Red1; RED1 homolog; RNA editase; RNA editing deaminase 1; RNA editing deaminase of glutamate receptors; RNA-editing deaminase 1; RNA-editing enzyme 1
• Gene Symbols: ADARB1
• Host Species: Rabbit
• Immunogen: Synthetic peptide directed towards the N terminal region of human ADARB1 (aa 8-57).
• Purification Method: Affinity chromatography
• Quantity: 100 μL
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 104
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov